World Sleep Industry ENCYCLOPEDIA

Transcranial Magnetic Stimulation Devices

2.3.3

Definition, electromagnetic principle, and category boundaries

A transcranial magnetic stimulation device rapidly discharges a capacitor through an insulated coil, producing a brief changing current and magnetic field. The field passes through the scalp and skull and induces an electric field in nearby brain tissue, where it can alter neuronal excitability. No current has to be injected directly through scalp electrodes, but the term noninvasive does not mean risk-free. The magnitude and direction of the cortical electric field depend on coil geometry and orientation, pulse waveform, stimulator output, coil-to-scalp distance, and individual skull, cerebrospinal-fluid, and cortical anatomy. The percentage shown on the console is therefore not a complete measure of delivered brain dose.

Single-pulse and paired-pulse systems are often used to assess motor conduction or cortical physiology and in research. Repetitive transcranial magnetic stimulation delivers pulse trains at defined frequencies and intervals, while patterned approaches include intermittent or continuous theta-burst stimulation. Magnetic seizure therapy intentionally induces a therapeutic seizure under anesthesia and follows a different risk and regulatory pathway; it must not be conflated with routine repetitive stimulation. TMS is also distinct from transcranial direct-current, alternating-current, or random-noise stimulation, electroconvulsive therapy, peripheral magnetic stimulation, and magnetic resonance imaging.

A system commonly includes the stimulator, capacitor and power electronics, one or more treatment coils with cooling and position-sensing components, control software, a treatment chair and head support, and optional targeting or navigation. Coil click sound, local magnetic fields, induced currents, and heat are all safety concerns. The term neuromodulation means that neural activity can be altered; it does not prove that every pulse selectively reaches one network or that a clinical effect is inevitable or permanent.

Device types, coils, targeting, and dose specification

A conventional figure-of-eight coil produces a relatively focal superficial cortical field, whereas a circular coil covers a broader area. H-coils and other deep-TMS designs may produce a broader field that extends relatively deeper, but deep does not mean selective access to any arbitrary subcortical nucleus. Coils differ in inductance, cooling, maximum repetition rate, and spatial field distribution and are not interchangeable merely because a connector can be made to fit. The coil, stimulator, software, and authorized protocol form a system; an unvalidated combination can change output, thermal load, targeting, and the safety envelope.

A reproducible prescription specifies at least the target and hemisphere, coil model and orientation, motor-threshold method, intensity relative to threshold, frequency, train duration, intertrain interval, pulses per session, number and spacing of sessions, intersession timing for an accelerated course, targeting method, and concomitant medication. Labels such as high frequency, low frequency, or deep stimulation are insufficient. A motor threshold is a physiological reference measured at a particular time with a particular coil and method, not a permanent patient trait. Medication, major sleep loss, clinical status, measurement quality, coil position, or device changes may require reassessment under the applicable protocol.

Targeting can use scalp measurements, a geometric displacement from the motor hotspot, structural MRI neuronavigation, or research methods based on functional connectivity. Navigation can record the relative position, angle, and displacement of the coil and head and improve geometric reproducibility. It does not prove that the induced field engages the intended network or guarantees response. Head support, coil contact, hair volume, operator pressure, and patient movement all alter practical delivery, so position should be checked during every session and meaningful deviations documented.

Product-specific indications and levels of evidence

An authorized use depends on jurisdiction and on the specific manufacturer, model, coil, software version, age range, disorder, prior-treatment conditions, and parameter set. Authorization of one system for major depressive disorder does not automatically authorize that system for obsessive-compulsive disorder, smoking cessation, migraine, post-traumatic stress disorder, or insomnia. Nor are different protocols for the same diagnosis automatically interchangeable. Regulatory authorization establishes a safety and performance threshold for defined use; it does not mean every patient will respond and does not replace diagnosis, informed consent, or follow-up.

Major depressive disorder is among the most established therapeutic applications of repetitive TMS, but patient selection and delivery must still follow the applicable labeling and professional standards. Monitoring should cover symptoms, function, suicidality, emerging mania or hypomania, medication changes, and adverse events. For other conditions, evidence should be separated into blinded randomized trials, open studies, case series, and mechanistic inference. A biomarker shift in a small study cannot substitute for a patient-important outcome, and short-term scale improvement does not establish durable relapse prevention.

Research use must be distinguished from routine clinical service. A study should prespecify or register its target and analysis, use credible sham stimulation and blinded outcome assessment, and report attrition, concomitant treatment, stimulation parameters, and adverse events. If the sham differs clearly in sound, scalp sensation, or facial movement, participants may infer allocation and subjective effects can be exaggerated. Marketing must not convert exploratory evidence, one jurisdiction's authorization, or one manufacturer's dataset into a class-wide promise of cure.

Patient screening, implants, and treatment preparation

Before treatment, a qualified clinician confirms the diagnosis and goal, asks about epilepsy, unexplained loss of consciousness, brain injury, stroke, tumor, and neurosurgery, and reviews medication withdrawal, drugs or substances that may change seizure threshold, alcohol use, severe sleep deprivation, fever, and metabolic disturbance. Hearing, headache, cervical disease, scalp integrity, pregnancy status, mental state, and the ability to understand and report symptoms are also relevant. Not every factor is an absolute contraindication, but each must enter an individualized decision and may justify consultation or postponement.

One of the most important screens concerns conductive or magnetic material and active implants in or near the head. Examples include cochlear implants, deep-brain or cortical electrodes, vagus-nerve stimulators, aneurysm clips or coils, stents, programmable shunt valves, infusion pumps, cardiac pacemakers or defibrillators, metallic fragments, and other electronic devices. Risk depends on composition, fixation, location, lead loops, electromagnetic immunity, and the treatment-system instructions. It is wrong both to prohibit every dental restoration categorically and to declare an implant safe from patient memory alone. The implant model and manufacturer conditions should be obtained and checked against both devices' labeling and institutional policy.

Before every session, staff verify patient identity, prescription, coil, program, target, threshold basis, and health or medication changes since the last visit. Hearing aids, jewelry, hair accessories, and other items specified by the manufacturer are removed. Hearing protection is inserted correctly and checked, a comfortable stable posture and head support are established, and the patient is told what common sensations to expect and how to request a stop. Emergency shutdown, staff roles, seizure and syncope response, resuscitation resources, and transfer pathways should be rehearsed before the first patient is treated.

Treatment delivery, monitoring, and emergency response

The operator identifies the motor hotspot or threshold and completes targeting under the authorized protocol, maintaining the specified coil orientation, contact, and cooling. Output may be advanced as permitted to improve tolerability, but pulse trains must not be compressed, stacked, or extended beyond the permitted duty cycle to save time. During treatment, staff observe alertness, speech and movement, pain, anxiety, facial contraction, dizziness, and possible aura. After meaningful patient movement, stimulation should pause and the position should be re-established rather than simply pulling a mechanical arm back toward a mark while pulses continue.

Common transient effects include scalp discomfort, local pain, facial or jaw muscle contraction, headache, neck discomfort, dizziness, and fatigue. Position, orientation, support, and an authorized ramp-up strategy can be checked, but reducing intensity or moving the target changes the protocol and requires an authorized decision and documentation. Tinnitus, hearing change, persistent or unusual headache, a neurological deficit, psychiatric deterioration, signs of mania, or suicide risk require prompt assessment and should not be dismissed as a normal activation response.

A seizure is uncommon but potentially serious. With abnormal movements, loss of responsiveness, or a suspected seizure, stimulation is stopped immediately, the patient is protected from falling or impact, the airway is supported, and trained staff time the event and summon help according to the emergency plan. Limbs should not be forcibly restrained and nothing should be placed in the mouth. Syncope can include brief movements and still requires trained assessment and documentation. Further stimulation is withheld while possible triggers, parameters, medications, sleep, and clinical changes are reviewed, required reports are completed, and a new risk-benefit decision is made.

Adverse effects, device safety, and operational maintenance

Beyond seizure and auditory risk, strong magnetic pulses can interfere with or damage nearby electronic or implanted devices, heat or move some metals, and affect cards, storage media, or instruments. A controlled treatment zone should restrict unscreened people and objects. Separation distances must come from the relevant manufacturers rather than a universal number copied from another model. When TMS is combined with an MRI environment, the separate MRI-conditional requirements also apply; an ordinary TMS coil is not MRI-safe merely because both technologies use magnetism.

Coils heat during repetitive pulsing, and systems may use air cooling, liquid cooling, and temperature interlocks. Operators inspect housings, insulation, cables, connectors, positioning hardware, cooling lines, and unusual odor or noise. They follow maximum duty cycles and cooling times and must not obstruct ventilation, bypass an over-temperature alarm, or continue with an unapproved coil. A damaged cable, fluid leak, drop, overheating episode, or abnormal output requires immediate removal from service, clear quarantine labeling, and assessment by qualified personnel.

Quality management covers procurement acceptance, room and electrical requirements, verification of output and timing performance, coil identification and field information, navigation accuracy, interlock and emergency-stop tests, software configuration, account and network security, cleaning and disinfection, preventive maintenance, calibration or manufacturer-specified performance checks, and recall management. The treatment record should trace device and coil serial numbers, software and protocol versions, parameters, location, threshold, operator, response, and interruption. Software updates, coil repair or replacement, room relocation, and introduction of a new protocol require change control and appropriate revalidation.

Sleep evidence, procurement governance, and quality conclusion

Repetitive TMS for primary or chronic insomnia remains an evolving research use. Improvement in a sleep questionnaire among patients treated for depression does not by itself establish direct efficacy for primary insomnia. Controlled trials and reviews report possible improvement in some subjective or objective sleep outcomes, but targets, frequencies, course lengths, sham methods, concomitant treatment, and populations vary substantially. Small samples, imperfect blinding, attrition, and risk of bias remain important. Recent studies include short-term positive signals as well as active-versus-sham results that were broadly similar or no longer different at follow-up, which is not a basis for indiscriminate routine use.

TMS does not splint the upper airway, deliver ventilation, or correct a defined respiratory event. It must not replace diagnostic assessment or disease-specific treatment such as positive airway pressure for obstructive sleep apnea. Reviews have not established a relevant clinical effect for obstructive sleep apnea or narcolepsy. A person with chronic insomnia should receive a structured evaluation and first have access to established options such as cognitive behavioral therapy for insomnia and treatment of comorbid disease. If stimulation is used in research or a compliant exceptional pathway, sleep outcomes, objective monitoring, follow-up, and stopping criteria should be defined in advance.

Procurement should not be based only on maximum output or a claim of stimulation depth. An institution verifies local authorization, precise indication and age range, compatible coils and protocols, pulse accuracy, cooling capacity, navigation and position tracking, patient and operator hearing protection, emergency stops and interlocks, data export, audit logs, cybersecurity, maintenance and calibration, consumables, and training support. Final quality comes from the combination of the right patient, product, protocol, reproducible placement, and ongoing monitoring. Advanced hardware cannot compensate for a wrong diagnosis, off-label promotional claims, or an unprepared emergency system.